ArticleBritish journal of cancer1998
Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma.
Article in British journal of cancer, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 122 citations in OpenAlex.
- Prognostication and monitoring of mesothelioma using biomarkers: a systematic review.British journal of cancer · 2017Pooled it
- Clinical and immunological assessment of Mycobacterium vaccae (SRL172) with chemotherapy in patients with malignant mesothelioma.British journal of cancer · 2002Trial
- Venous Thromboembolism in Peritoneal Mesothelioma: Uncovering the Hidden Risk.Annals of surgical oncology · 2024Article
- Targeting interleukin-6 as a treatment approach for peritoneal carcinomatosis.Journal of translational medicine · 2024Review
- C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel.Scientific reports · 2023Article
- Inflammation as a chemoprevention target in asbestos-induced malignant mesothelioma.Carcinogenesis · 2022Article
- Sarcopenia as a Predictor of Short- and Long-Term Outcomes in Patients Surgically Treated for Malignant Pleural Mesothelioma.Cancers · 2022Article
- Mesothelioma with Nonbacterial Thrombotic Endocarditis: A Case Report.JNMA; journal of the Nepal Medical Association · 2021Article
- Article
- Overexpression of microRNA‑486 affects the proliferation and chemosensitivity of mesothelioma cell lines by targetingInternational journal of molecular medicine · 2021Article
- Review
- A Case of Pulmonary Embolism with Sarcomatoid Malignant Pleural Mesothelioma with Long-Term Pleural Effusion.OncoTargets and therapy · 2021Article
- Serum mesothelin and other biomarkers: what have we learned in the last decade?Journal of thoracic disease · 2018Review
- Review
- Article
- The proliferative effects of asbestos-exposed peripheral blood mononuclear cells on mesothelial cells.Oncology letters · 2016Article
- Comparative proteomic analysis of malignant pleural mesothelioma: Focusing on the biphasic subtype.EuPA open proteomics · 2016Article
- Thrombocytosis and Raised CRP Levels Predicts Advanced Stage in Esophageal Carcinoma.Journal of gastrointestinal cancer · 2015Article
- Prognostic significance of preoperative platelet count in patients with gallbladder cancer.World journal of gastroenterology · 2015Article
- The role of interleukin-6 in malignant mesothelioma.Translational lung cancer research · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The relationship between interleukin 6 (IL-6) levels and clinical parameters was studied in 25 patients with malignant pleural mesothelioma. The serum levels of IL-6, C-reactive protein, alpha1-acid glycoprotein and fibrinogen were significantly higher in mesothelioma than in lung adenocarcinoma with cytology-positive pleural effusion. Serum IL-6 levels correlated with the levels of the acute-phase proteins. We demonstrated a high incidence of thrombocytosis (48%) and a significant correlation between platelet count and the serum IL-6 level. The level of IL-6 in the pleural fluid of patients with mesothelioma was significantly higher than in the pleural fluid of patients with adenocarcinoma, and was about 60-1400 times higher than in the serum. However, even higher levels of IL-6 in the pleural fluid and of thrombocytosis were found in patients with tuberculous pleurisy. These results indicate that large amounts of IL-6 from the pleural fluid of patients with mesothelioma leak into the systemic circulation and induce clinical inflammatory reactions. These profiles are not specific to mesothelioma as similar profiles are found in patients with tuberculous pleurisy. However, the detection of a markedly increased level of IL-6 in pleural fluid argues against a diagnosis of adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.